Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Sara Saberi et al.|The Lancet|2020Cited by 1.2k
The continuous heart failure spectrum: moving beyond an ejection fraction classificationFilippos Triposkiadis, Gilles W. De Keulenaer, Javed Butler et al.|European Heart Journal|2019Cited by 258
Organization of Heart Failure Management in European Society of Cardiology Member Countries: Survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working GroupsPetar Seferović, Stefan D. Anker, Gerasimos Filippatos et al.|European Journal of Heart Failure|2013Cited by 83